Aadi Bioscience, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.aadibio.com

Moat Score

Market Cap $60.33M
PE -1
Debt $NaN
Cash $30.54M
EV $NaN
FCF -$56.43M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$61.69M
EBIT	-$64.78M
ROE	-90%
ROA	-76%
FCF	-$56.43M
Equity	$68.87M
Growth Stability	1
PE	-0.98
PB	0.88
P/FCF	-1.07
P/S	2.41
Price/Cash	0.51
Net Margins	-242%
Gross Margins	87%
Op. Margins	-258%
Sales Growth YoY	21%
Sales Growth QoQ	17%
Sales CAGR	6%
Equity CAGR	25%
Earnings Growth YoY	-23%
Earnings Growth QoQ	-14%

Sales CAGR 5Y	131%
Equity CAGR 5Y	28%
Earnings CAGR 3Y	20%
Sales CAGR 3Y	20%
Equity CAGR 3Y	-20%
Market Cap	$60.33M
Revenue	$25.07M
Dividend Yield	0%
Payout Ratio	-0%
Assets	$85.70M
Cash	$30.54M
Shares Outstanding	24.61M
Moat Score	1%
Working Capital	61.5M
Current Ratio	4.89
Gross Profit	$21.91M
Shares Growth 3y	7%
Equity Growth QoQ	-13%
Equity Growth YoY	-42%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.

SEC Filings

Direct access to Aadi Bioscience, Inc. (AADI) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Aadi Bioscience, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Aadi Bioscience, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Aadi Bioscience, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Aadi Bioscience, Inc..

Years

Calculation mode

= -$564M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$56M	-$56M	-$56M	-$56M	-$56M	-$56M	-$56M	-$56M	-$56M	-$56M	-$56M	-$564M
DCF		-$51M	-$47M	-$42M	-$39M	-$35M	-$32M	-$29M	-$26M	-$24M	-$22M	-$218M
Value	-$564M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-52%	-	-29%	-791%	-398%	-270%	-242%
ROA	-	-124%	-735%	-102%	-17%	-61%	-8%	-70%	-33%	-50%	-76%
ROE	-	17%	9K%	-128%	-18%	-64%	-10%	-81%	-38%	-63%	-90%

Bad Net Margins (-242.31%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-1.87	-	-	-	-
Debt over Equity	-	-	-54.83	-	-	-	0.24	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-100%	-	-7%	9%	60%	131%
Earnings YoY growth	-	-85%	66K%	7%	-53%	124%	-81%	2K%	-45%	9%	-
Equity YoY growth	-	20%	21%	-8K%	236%	-38%	18%	217%	16%	-34%	28%
FCF YoY growth	-	-	-	14K%	-69%	312%	-78%	316%	123%	27%	-